BEND2

Across TCGA pan-cancer cohorts, BEND2 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated BEND2 data layer compared with 20 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher BEND2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated BEND2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LUSC, UCEC, and BLCA are the cancer types where BEND2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	III,IV	0.206	0.581	.009	32	view →
UCEC	DFS	Median	All	0.958	0.827	.020	20	view →
BLCA	DFS	Median	IV	0.090	0.469	.009	12	view →
STAD	OS	Median	II,III,IV	0.041	0.660	<.001	12	view →
LIHC	DFS	Median	All	0.148	0.555	.023	6	view →
LUAD	OS	Median	II,III,IV	0.211	0.681	.007	6	view →
COAD	OS	Median	All	0.639	0.877	.008	3	view →
SKCM	OS	Median	IV	0.415	0.861	.014	3	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

BEND2–LUSC (OS)

Open the LUSC breakdown →